ArticleJournal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures)2026
Evaluation of presepsin dynamics in septic patients with and without liver cirrhosis.
Article in Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis is associated with high short-term mortality, particularly in patients with decompensated liver cirrhosis. Conventional inflammatory biomarkers have limited prognostic accuracy in this population. Presepsin has emerged as a promising biomarker; however, its dynamic behavior in early sepsis remains insufficiently characterized. Objectives: To evaluate the prognostic value of presepsin dynamics in sepsis, with and without underlying liver cirrhosis, and to compare it with established inflammatory markers. Methods: We conducted an observational cohort study including two patient groups: patients with sepsis and de-compensated liver cirrhosis (Group A) and patients with sepsis without cirrhosis (Group B). Presepsin levels were measured at admission and after 48 hours, and delta presepsin was calculated. Prognostic performance was assessed using receiver operating characteristic (ROC) analysis and Cox proportional hazards regression. The primary endpoint was 28-day mortality. Results: In Group A, presepsin measured at 48 hours demonstrated superior prognostic performance compared with baseline levels (AUROC 0.91 vs. 0.78). Changes in presepsin further enhanced risk stratification, with a negative delta associated with improved survival, whereas an increase of ≥500 pg/mL was independently associated with higher mortality. (HR 5, 95% CI:1.64-15.26). In Group B presepsin showed moderate prognostic performance at baseline and 48 hours, whereas delta presepsin demonstrated limited overall accuracy, except in patients with positive delta values. Established biomarkers, including C-reactive protein and procalcitonin, showed inferior prognostic performance compared with presepsin in both cohorts. Conclusions: Dynamic assessment of presepsin provides clinically relevant prognostic information in sepsis, particularly in patients with decompensated liver cirrhosis. Early changes in presepsin levels may enhance risk stratification beyond conventional inflammatory biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.